Peregrine Capital Management LLC Buys 36,958 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Peregrine Capital Management LLC grew its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 12.1% during the fourth quarter, HoldingsChannel reports. The firm owned 342,845 shares of the company’s stock after purchasing an additional 36,958 shares during the quarter. Peregrine Capital Management LLC’s holdings in Myriad Genetics were worth $4,700,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the stock. Creative Planning boosted its stake in Myriad Genetics by 9.8% during the third quarter. Creative Planning now owns 9,949 shares of the company’s stock worth $273,000 after acquiring an additional 892 shares in the last quarter. Blue Trust Inc. boosted its stake in Myriad Genetics by 12.5% during the third quarter. Blue Trust Inc. now owns 12,663 shares of the company’s stock worth $347,000 after acquiring an additional 1,404 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Myriad Genetics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,285 shares of the company’s stock worth $87,000 after acquiring an additional 583 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in Myriad Genetics by 182.9% during the third quarter. Nisa Investment Advisors LLC now owns 11,417 shares of the company’s stock worth $313,000 after acquiring an additional 7,381 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Myriad Genetics by 64.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 17,468 shares of the company’s stock worth $478,000 after acquiring an additional 6,834 shares in the last quarter. Institutional investors own 99.02% of the company’s stock.

Wall Street Analyst Weigh In

MYGN has been the topic of several research reports. UBS Group initiated coverage on shares of Myriad Genetics in a research note on Tuesday, December 10th. They set a “neutral” rating and a $18.00 price objective on the stock. The Goldman Sachs Group dropped their price objective on shares of Myriad Genetics from $29.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. StockNews.com raised shares of Myriad Genetics from a “hold” rating to a “buy” rating in a report on Thursday, January 9th. Craig Hallum initiated coverage on shares of Myriad Genetics in a report on Wednesday, February 12th. They issued a “buy” rating and a $29.00 target price for the company. Finally, Leerink Partnrs cut shares of Myriad Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, December 9th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Myriad Genetics presently has a consensus rating of “Hold” and an average price target of $22.54.

Myriad Genetics Trading Up 2.3 %

Shares of NASDAQ:MYGN opened at $14.90 on Thursday. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -11.46 and a beta of 1.88. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. The stock’s 50-day simple moving average is $13.45 and its two-hundred day simple moving average is $19.69. Myriad Genetics, Inc. has a 52-week low of $12.04 and a 52-week high of $29.30.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.